Evaluation of Daily HemoDialysis at Low Dialysate Flow in Patients Previously Treated With Conventional Hemodialysis (HDQ200)

HDQ 200 is an interventional multicenter study. This is a before-and-after design in which the patient is his own control. The main objective of the study is to determine the percentage of success of a procedure of daily hemodialysis at low dialysate flow. All patients treated with conventional hemodialysis, for at least 3 months and clinically stable, can be included in the study. Their 3 months data prior to inclusion is collected retrospectively. These 3 months of conventional hemodialysis are the reference period. Patients are then treated with daily hemodialysis at low dialysate flow for 3 months. During this 3 months period, the same data as during the period of conventional hemodialysis are collected prospectively.

Study Overview

• Status: Terminated
• Conditions: End Stage Renal Disease
• Intervention / Treatment: Other: Daily hemodialysis at low dialysate flow

• Study Type: Interventional
• Enrollment (Actual): 2
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Belgium
  • Bruxelles, Belgium, 1200
    • Cliniques Universitaires St Luc
• France
  • Angers, France, 49055
    • ECHO Angers
  • Bordeaux, France, 33000
    • CTMR Saint Augustin
  • Cherbourg, France, 50102
    • CHPC
  • Grenoble, France, 38043
    • CHU Grenoble
  • Le Petit Quevilly, France, 76143
    • ANIDER
  • Lyon, France, 69008
    • AURAL
  • Lyon, France, 69437
    • Hospices Civils de lyon - Hôpital Edouard Herriot
  • Meylan, France, 38240
    • AGDUC Meylan
  • Paris, France, 75015
    • AURA - Paris
  • Pierre-benite, France, 69495
    • Hospices Civils de Lyon - Centre Hospitalier Lyon Sud
  • Reze, France, 44402
    • ECHO Nantes
  • Vichy, France, 03201
    • Centre Hospitalier de Vichy

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age ≥ 18 years
• Patients who give voluntary signed informed consent
• Patients affiliated with the French universal health care system or similar
• For women of childbearing potential: serum or urine negative pregnancy test
• Patients treated with conventional hemodialysis (3 times 4h to 5h per week at at least a dialysate flow rate of 500 ml/min) for at least 3 months and clinically stable (investigator assessment)
• Bipuncture patients (or with double lumen central venous catheter) with stable vascular access and easy to puncture
• Patients willing to be treated with daily hemodialysis at low dialysate flow during the study period (6 times 2h to 2h30 per week at a dialysate flow rate of 200 ml/min in order that the total duration of weekly dialysis is equivalent to the duration of weekly dialysis during the last 3 months of conventional hemodialysis)

Exclusion Criteria:

• Pregnant women or women who could become pregnant during the study (planned pregnancy within 3 months)
• Patients not affiliated with the French universal health care system
• Minor patients
• Patients who are protected adults according to the terms of the law (French public health laws).
• Refusal to give consent
• Patients simultaneously participating in another trial that may interfere with the study results

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Daily hemodialysis at low dialysate flow

Other: Daily hemodialysis at low dialysate flow; Daily hemodialysis at low dialysate flow during 3 months: 6 times 2h to 2h30 per week at a dialysate flow rate of 200 ml/min in order that the total duration of weekly dialysis is equivalent to the duration of weekly dialysis during the last 3 months of conventional hemodialysis. Other parameters of dialysis (dialysate, dialysis machine, generator, blood flow, anticoagulation) are the same as the reference period of conventional hemodialysis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients for whom the period of daily hemodialysis at low dialysate flow will be a success.	Definition of success: if during the period of daily hemodialysis at low dialysate flow, the patient maintains the absolute value of their pre-dialysis serum creatinine (mid-week dialysis) below the upper limit of the confidence interval established during the 3 months prior to inclusion on 7 values: measurements every 2 weeks for 3 months (retrospective data) and inclusion measurement included (Day 0). Daily hemodialysis at low dialysate flow will be considered as a failure if pre-dialysis serum creatinine values exceed twice successively the upper limit of the confidence interval established for the patient.	Every 2 weeks during 3 months.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients who stopped the daily hemodialysis at low dialysate flow (patient or investigator's decision).		3 months.
Number of patients who maintained a satisfactory clinical condition (investigator assessment) during the period of daily hemodialysis at low dialysate flow.		3 months.
Evaluation of weight.	The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): every 2 weeks.	During 3 months (retrospectively and prospectively).
Evaluation of blood pressure.	The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): every 2 weeks.	During 3 months (retrospectively and prospectively).
Evaluation of heart rate.	The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): every 2 weeks.	During 3 months (retrospectively and prospectively).
Evaluation of body mass index.	The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): every 2 weeks.	During 3 months (retrospectively and prospectively).
Evaluation of metabolic parameters.	The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): every 2 weeks.	During 3 months (retrospectively and prospectively).
Evaluation of hematological parameters.	The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): every 2 weeks.	During 3 months (retrospectively and prospectively).
Evaluation of inflammation parameters.	The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): monthly.	During 3 months (retrospectively and prospectively).
Evaluation of nutrition parameters.	The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): monthly.	During 3 months (retrospectively and prospectively).
Evaluation of iron parameters.	The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): monthly.	During 3 months (retrospectively and prospectively).
Change in hormones.	Measurement at inclusion represent the retrospective period of 3 months in conventional hemodialysis. Measurement at 3 months represent the prospective period of 3 months in daily hemodialysis at low dialysate flow.	At inclusion and at 3 months.
Composite measurement of treatments.	The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): at each hemodialysis. A listing of all the therapeutics changes made between the two dialysis periods will be provided (e.g. dose of erythropoietin, phosphate binders, antihypertensive drugs, other treatments)	During 3 months (retrospectively and prospectively).
Composite measurement of technical dialysis parameters.	The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): every 2 weeks. A listing of all the technical dialysis changes made between the two dialysis periods will be provided (e.g. urea clearance of the dialysis machine, effective duration of dialysis, ultrafiltration time rate and per dialysis, type of access, blood flow, dialysate flow rate, dialysate composition and anticoagulation method).	During 3 months (retrospectively and prospectively).
List of symptoms and incidents between two hemodialysis, evaluation of hemodialysis tolerance, clinical assessment of the vascular access and possible local complications.	The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow.	At each hemodialysis during 3 months (retrospectively and prospectively).
Change in quality of life.	Measurement at inclusion represent the retrospective period of 3 months in conventional hemodialysis. Measurement at 3 months represent the prospective period of 3 months in daily hemodialysis at low dialysate flow.	At inclusion and at 3 months.
Change in pain.	Measurement at inclusion represent the retrospective period of 3 months in conventional hemodialysis. Measurement at 3 months represent the prospective period of 3 months in daily hemodialysis at low dialysate flow.	At inclusion and at 3 months.

Collaborators and Investigators

• Sponsor: Association Pour L'utilisation Rein Artificiel Région Lyonnaise
• Collaborators: Association Nationale pour la promotion de la Dialyse Quotidienne (ANDIQ, France)
• Investigators: Principal Investigator: Maurice Laville, MD, PHD, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service de Néphrologie Bâtiment 3C, 3ème étage, Chemin du grand Revoyet 69495 PIERRE-BENITE

Study record dates

Study Major Dates

• Study Start: July 1, 2012
• Primary Completion (Actual): January 1, 2015
• Study Completion (Actual): January 1, 2015

Study Registration Dates

• First Submitted: April 11, 2013
• First Submitted That Met QC Criteria: April 30, 2013
• First Posted (Estimate): May 3, 2013

Study Record Updates

• Last Update Posted (Actual): March 17, 2017
• Last Update Submitted That Met QC Criteria: March 16, 2017
• Last Verified: March 1, 2017

More Information

Terms related to this study

• Keywords: End stage renal disease; Short daily hemodialysis; Low dialysate flow
• Additional Relevant MeSH Terms: Urologic Diseases; Renal Insufficiency; Renal Insufficiency, Chronic; Kidney Diseases; Kidney Failure, Chronic; Pharmaceutical Solutions; Dialysis Solutions
• Other Study ID Numbers: 2012-A00307-36